Notably metformin was also taken by 2 participants with NGT (one with a history of polycystic ovary syndrome and one diagnosed with insulin resistance) and 1 with PRED (indication of metformin therapy unknown), Additionally, 2% of participants with T1D were treated with SGLT-2 inhibitors (Table 3). The gene discussed is SLC5A2; the disease is Insulin resistance.